AstraZeneca (AZN) said Friday it plans to invest $2.5 billion in a new research and development hub in China as the drugmaker tries to reignite ...

AstraZeneca (AZN) announced an investment of $2.5B in Beijing to establish its sixth global strategic R&D center together with major ...

What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...

The suspected death was reported by authorities on Friday. Story continues below this ad One suspected GBS case was also identified and overall there are 225 GBS cases in Pune since January this year.

Drug firm AstraZeneca Pharma India Ltd on Friday (March 7) said it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import, sell, and distribute durvalumab ...

Guillain-Barre Syndrome (pronounced Gee-luhn-Baa Syndrome) or GBS is a rare autoimmune condition in which the immune system attacks the peripheral nerves. It leads to symptoms such as numbness ...

Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...

Blog posts represent the views of CFR fellows and staff and not those of CFR, which takes no institutional positions. President Donald Trump’s first month in office has been dizzying for U.S ...

AstraZeneca and Future Biogas today announced that the UK’s first unsubsidized biomethane plant dedicated to fuelling the life sciences sector is now operational. Located in Gonerby Moor, Lincolnshire ...

Only a very small percentage of persons who receive vaccinations can acquire GBS. Covishield is the brand name used in India to commercialize the Oxford-AstraZeneca COVID-19 vaccination.

The recent outbreak of Guillain-Barré Syndrome (GBS) in Maharashtra has raised concerns about the potential role of contaminated food and water. While the exact cause of the outbreak is still under ...

As­traZeneca wasn’t ex­pect­ed to have da­ta from the Phase 3 tri­al of its oral SERD un­til the sec­ond half of this year so the pos­i­tive … ...